BioAge Labs Q3 net loss $23.4M; IPO proceeds extend cash runway into 2029

BioAge Labs, Inc.

2024-Q3 EPS reported -$21.76

Net loss of $23.4M ($6.70/share) vs $14.6M ($8.74/share) in Q3 2023; R&D spend rose to $20.0M on Phase 2 STRIDES trial.
Cash and cash equivalents at Sept. 30, 2024: $334.5M, with additional $27.6M from underwriter option in Oct. 2024.
IPO and concurrent private placement yielded ~$189.5M net, plus $27.6M from underwriter option; cash sufficient into 2029.
Phase 2 STRIDES trial of azelaprag + tirzepatide for obesity dosed first patient; top-line results expected Q3 2025.
Appointed former GSK CEO Jean-Pierre Garnier as Board Chair, succeeding James Healy who remains a director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.